Zim Laboratories Limited has informed the Exchange about Transcript

Zim Laboratories held its Q4 & FY26 earnings call where management discussed regulatory progress and financial performance. The EU GMP re-inspection was completed May 4-7, 2026 by German and Portuguese authorities, with management expecting a positive outcome within approximately 2 months pending CAPA submission. Q4 FY26 revenue was INR 1,053 million with EBITDA of INR 134 million (12.7% margin), while FY26 full-year revenue stood at INR 3,744 million (flat YoY) impacted by ~INR 20-25 crore from MENA geopolitical disruptions and EU GMP-related constraints. The company has 17 products in its NIP and OTF pipeline expected to be fully commercialized over 24 months, targeting 50% of business from innovative products. EBITDA margins are expected to reach upper teens once regulated markets resume. The company also received marketing approval for Dabigatran capsules in Italy (EU market size $400 million). R&D spend remained at 8.3% of revenue with similar levels expected for FY27.